July 13, 2018

Siemens Healthcare Diagnostics Inc.   
Alan Haley   
Regulatory and Clinical Affairs Specialist 500 GBC Drive   
Newark, DE 19702

Re: K173909 Trade/Device Name: Dimension Hemoglobin A1c Assay Regulation Number: 21 CFR 862.1373 Regulation Name: Hemoglobin A1c test system Regulatory Class: Class II Product Code: PDJ Dated: June 11, 2018 Received: June 12, 2018

Dear Alan Haley:

We have reviewed your Section $5 1 0 ( \mathrm { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR

803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice   
(https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn   
(http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

# Kellie B. Kelm -S

Courtney H. Lias, Ph.D.GPS Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

Enclosure

510(k) Number (if known) N

Device Name Dimension $^ \mathrm { \textregistered }$ Hemoglobin A1c Assay

Indications for Use (Describe)   
The Dimension $^ \mathrm { \textregistered }$ Hemoglobin A1c assay is an in vitro diagnostic assay for the quantitative determination of $\% _ { \mathrm { \tiny \mathrm { ~ H b A l { c } } } }$ (DCCT/NGSP) and mmol/mol HbA1c (IFCC) in human anticoagulated venous whole blood for use on the Dimension $^ \mathrm { \textregistered }$ clinical chemistry system. Measurement of Hemoglobin A1c is used as an aid in diagnosis and monitoring of long-term blood glucose control in patients with diabetes mellitus and as an aid in the identification of patients at risk for developing diabetes mellitus.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”

# SIEMENS

# 510(k) Summary – K173909

This 510(k) Summary of Safety and Effectiveness is being submitted in accordance with the requirements of Safe Medical Device Act of 1990 and 21 CFR 807.92.

# 1. Submitter

<table><tr><td>Company</td><td>Siemens Healthcare Diagnostics Inc.</td></tr><tr><td>Address</td><td>500 GBC Drive Newark, DE 19702</td></tr><tr><td>Contact</td><td></td></tr><tr><td></td><td>Alan Haley</td></tr><tr><td>Telephone</td><td>302.631.9883</td></tr><tr><td>Fax</td><td>302.631.6299</td></tr><tr><td>Date of Preparation</td><td>July 12, 2018</td></tr></table>

# 2. Device Information

<table><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=1>Dimension® Hemoglobin A1C Assay</td></tr><tr><td rowspan=1 colspan=1>Common Name</td><td rowspan=1 colspan=1>Hemoglobin A1c Test System</td></tr><tr><td rowspan=1 colspan=1>Classification Name</td><td rowspan=1 colspan=1>Hemoglobin A1c Test System</td></tr><tr><td rowspan=1 colspan=1>Regulation</td><td rowspan=1 colspan=1>21 CFR 862.1373</td></tr><tr><td rowspan=1 colspan=1>Device Class</td><td rowspan=1 colspan=1>Class II</td></tr><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>PDJ</td></tr><tr><td rowspan=1 colspan=1>Panel</td><td rowspan=1 colspan=1>Clinical Chemistry</td></tr></table>

# 3. Identification of Predicate

<table><tr><td rowspan=1 colspan=1>Trade Name</td><td rowspan=1 colspan=1>Roche Diagnostics Operations (RDO)</td></tr><tr><td rowspan=1 colspan=1>510(k) Submitter</td><td rowspan=1 colspan=1>Cobas C13 Tina-Quant HbA1cDx Gen.3 Assay</td></tr><tr><td rowspan=1 colspan=1>510(k) Number</td><td rowspan=1 colspan=1>K160571</td></tr><tr><td rowspan=1 colspan=1>Clearance Date</td><td rowspan=1 colspan=1>December 19, 2016</td></tr></table>

# 4. Device Description

The Dimension® Hemoglobin A1C assay is an in vitro diagnostic device intended to measure the concentration of hemoglobin A1c in venous human anticoagulated whole blood. The assay consists of three reagents packaged in Dimension® Flex® cartridges. The reagents are liquid and ready to use.

# 5. Intended Use Statement

The Dimension® Hemoglobin A1C assay is an in vitro diagnostic assay for the quantitative determination of %HbA1c (DCCT/NGSP) and mmol/mol HbA1c (IFCC) in human anticoagulated venous whole blood for use on the Dimension® clinical chemistry system. Measurement of Hemoglobin A1c is used as an aid in diagnosis and monitoring of long-term blood glucose control in patients with diabetes mellitus and as an aid in the identification of patients at risk for developing diabetes mellitus.

# SIEMENS

6. Technological Characteristics

(a) Similarities and Differences

<table><tr><td colspan="1" rowspan="1">DeviceCharacteristic</td><td colspan="1" rowspan="1">Predicate DeviceCobas C13 Tina-QuantHbA1cDx Gen.3 Assay(K160571)</td><td colspan="1" rowspan="1">Proposed DeviceDimesionHemoglobin A1C Assay</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">This test is intended for use as anaid in diagnosis of diabetes andas an aid in identifying patientswho may be at risk for developingdiabetes. It is an in vitrodiagnostics reagent systemintended for quantitativedetermination of mmol/molhemoglobin A1c (IFCC) and %hemoglobin A1c (DCCT/NGSP) inhemolysate or whole blood on theRoche/Hitachi cobas c 513clinical chemistry analyzer.HbA1c determinations are usefulfor monitoring of long-term bloodglucose control in individuals withdiabetes mellitus.</td><td colspan="1" rowspan="1">The Dimension® HemoglobinA1C assay is an in vitrodiagnostic assay for thequantitative determination of%HbA1c (DCCT/NGSP) andmmol/mol HbA1c (IFCC) inhuman anticoagulated venouswhole blood for use on theDimension® clinical chemistrysystem. Measurement ofHemoglobin A1c is used as anaid in diagnosis and monitoringof long-term blood glucosecontrol in patients with diabetesmellitus and as an aid in theidentification of patients at riskfor developing diabetes mellitus.</td></tr><tr><td colspan="1" rowspan="1">Type of Test</td><td colspan="1" rowspan="1">Quantitative turbidimetricinhibition immunoassay</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Measurand</td><td colspan="1" rowspan="1">Whole blood GlycosylatedHemoglobin (HbA1c)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reporting Units</td><td colspan="1" rowspan="1">% HbA1c NGSP/DCCT andmmol/mol IFCC</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">MeasuringRanges</td><td colspan="1" rowspan="1">Hemoglobin4 to 35 g/dL(2.48 to 21.7 mmol/L)HbA1c0.3 to 3.4 g/dL(0.186 to 2.11 mmol/L)%HbA1c4.2 to 15.5%(23 to 146 mmol/mol)</td><td colspan="1" rowspan="1">Hemoglobin5.0 to 25.0 g/dL(3.1 to 15.5 mmol/L)HbA1c0.25 to 2.90 g/dL(0.16 to 1.80 mmol/L)%HbA1c3.8 to 14.0%(18 to 130 mmol/mol)</td></tr><tr><td colspan="1" rowspan="1">InstrumentPlatform</td><td colspan="1" rowspan="1">Cobas c 513(absorbance spectroscopy)</td><td colspan="1" rowspan="1">Dimension® RxL clinicalchemistry system(absorbance spectroscopy)</td></tr><tr><td colspan="1" rowspan="1">Anticoagulants</td><td colspan="1" rowspan="1">Li-Heparin-EDTAK3-EDTAEDTA/Fluoride</td><td colspan="1" rowspan="1">K2-EDTAK3-EDTANa Fluoride/Na2-EDTALithium HeparinNa Fluoride/ K-Oxalate</td></tr><tr><td colspan="1" rowspan="1">DeviceCharacteristic</td><td colspan="1" rowspan="1">Predicate DeviceCobas C13 Tina-QuantHbA1cDx Gen.3 Assay(K160571)</td><td colspan="1" rowspan="1">Proposed DeviceDimmesionHemoglobin A1C Assay</td></tr><tr><td colspan="1" rowspan="1">CalibrationFrequency</td><td colspan="1" rowspan="1">Each lot, every 29 days, and asrequired following quality controlprocedures</td><td colspan="1" rowspan="1">Each lot, every 30 days, and asrequired following quality controlprocedures</td></tr><tr><td colspan="1" rowspan="1">ReagentStability</td><td colspan="1" rowspan="1">Unopened2 - 8°C until expiration dateOn-board in use2  8°C for 28 days</td><td colspan="1" rowspan="1">Unopened2 - 8°C until expiration dateOn-board sealed2  8°C for 30 days</td></tr><tr><td colspan="1" rowspan="1">Antibody</td><td colspan="1" rowspan="1">Polyclonal anti-HbA1c, ovine</td><td colspan="1" rowspan="1">Same</td></tr></table>

# (b) Non-Clinical Performance Evaluation

# (i) Method Comparison

Method comparison testing was performed in accordance with CLSI EP09-A3, Measurement Procedure Comparison and Bias Estimation Using Patient Samples; Approved Guideline – Third Edition. 147 human whole blood samples with values spanning the assay range were tested using the Dimension® Hemoglobin A1C Assay on the Dimension® RxL clinical chemistry system. Assay results were compared to NGSP reference method results from testing performed at an NGSP reference laboratory. Sample distribution is shown in Table A. Slope and Y-intercept results were generated with both Passing-Bablok and Deming regressions. Results are presented in Tables B, C, D, and E.

Table A. Method Comparison Sample Distribution   

<table><tr><td rowspan=1 colspan=1>Range of Results(%HbA1c)</td><td rowspan=1 colspan=1>Percentage ofSamples</td><td rowspan=1 colspan=1>Number ofSamples</td></tr><tr><td rowspan=1 colspan=1>&lt;5</td><td rowspan=1 colspan=1>4.8%</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>5 to 6</td><td rowspan=1 colspan=1>12.2%</td><td rowspan=1 colspan=1>18</td></tr><tr><td rowspan=1 colspan=1>6 to 6.5</td><td rowspan=1 colspan=1>20.4%</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>6.5 to 7</td><td rowspan=1 colspan=1>21.8%</td><td rowspan=1 colspan=1>32</td></tr><tr><td rowspan=1 colspan=1>7 to 8</td><td rowspan=1 colspan=1>14.3%</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=1 colspan=1>8 to 9</td><td rowspan=1 colspan=1>8.2%</td><td rowspan=1 colspan=1>12</td></tr><tr><td rowspan=1 colspan=1>&gt; 9</td><td rowspan=1 colspan=1>18.4%</td><td rowspan=1 colspan=1>27</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>147</td></tr></table>

Table B. Method Comparison, Passing-Bablok   

<table><tr><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-int.[95% CI]</td></tr><tr><td rowspan=1 colspan=1>NGSP(%HbA1c)</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>0.983[0.966 to 1.001]</td><td rowspan=1 colspan=1>0.030[-0.095 to 0.144]</td></tr><tr><td rowspan=1 colspan=1>IFCC(mmol/mol HbA1c)</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>0.973[0.955 to 0.992]</td><td rowspan=1 colspan=1>0.437[-0.474 to 1.450]</td></tr></table>

# SIEMENS

Table C. Bias Estimations, Passing-Bablok   

<table><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.05</td><td rowspan=1 colspan=1>-1.10</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-0.08</td><td rowspan=1 colspan=1>-1.24</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-0.11</td><td rowspan=1 colspan=1>-1.33</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-0.17</td><td rowspan=1 colspan=1>-1.45</td></tr></table>

Table D. Method Comparison, Deming   

<table><tr><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-int.[95% CI]</td></tr><tr><td rowspan=1 colspan=1>NGSP(%HbA1c)</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>0.978[0.957 to 1.000]</td><td rowspan=1 colspan=1>0.052[-0.094 to 0.198]</td></tr><tr><td rowspan=1 colspan=1>IFCC(mmol/mol HbA1c)</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>0.970[0.948 to 0.992]</td><td rowspan=1 colspan=1>0.532[-0.603 to 1.666]</td></tr></table>

Table E. Bias Estimations, Deming   

<table><tr><td rowspan=1 colspan=1>%HbA1c</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>% Bias</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-0.06</td><td rowspan=1 colspan=1>-1.16</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-0.09</td><td rowspan=1 colspan=1>-1.40</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-0.12</td><td rowspan=1 colspan=1>-1.55</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-0.21</td><td rowspan=1 colspan=1>-1.77</td></tr></table>

# (ii) Precision

Precision testing was performed in accordance with CLSI EP05-A3, Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline – Third Edition. Samples consisted of two (2) commercial quality controls and four (4) whole blood patient pools with target values of $5 . 0 \%$ , $6 . 5 \%$ , $8 . 0 \%$ , and $1 2 . 0 \%$ HbA1c. Testing was performed over twenty (20) testing days by two (2) operators using three (3) instruments and three (3) reagent lots on each instrument. One (1) calibration was performed over the duration of the study. Each testing day, two (2) runs were performed (with a minimum of 2 hours in between) for a total of 80 results for each sample. Data were analyzed using Analysis of Variance (ANOVA), consistent with the recommendations of CLSI EP05-A3. Results are presented in Tables F and G.

Table F. Precision, All Instruments, NGSP Units (%HbA1c)   

<table><tr><td rowspan=2 colspan=1>SAMPLE</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeat-ability</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>MDP1</td><td rowspan=1 colspan=1>5.3</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>0.07</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>MDP2</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>MDP3</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>MDP4</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>0.09</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.18</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.22</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.05</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.11</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>2.6</td></tr><tr><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>9.5</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.06</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>0.16</td><td rowspan=1 colspan=1>1.7</td></tr></table>

Units: $S D = \%$ HbA1c, $C V = \%$

Table G. Precision, All Instruments, IFCC Units (mmol/mol HbA1c)   

<table><tr><td rowspan=2 colspan=1>SAMPLE</td><td rowspan=2 colspan=1>Mean</td><td rowspan=1 colspan=2>Repeat-ability</td><td rowspan=1 colspan=2>BetweenRun</td><td rowspan=1 colspan=2>BetweenDay</td><td rowspan=1 colspan=2>BetweenInstrument</td><td rowspan=1 colspan=2>BetweenLot</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>CV</td></tr><tr><td rowspan=1 colspan=1>MDP1</td><td rowspan=1 colspan=1>35</td><td rowspan=1 colspan=1>0.54</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.08</td><td rowspan=1 colspan=1>0.2</td><td rowspan=1 colspan=1>0.81</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>1.42</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1>MDP2</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0.52</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.95</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.17</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>MDP3</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.28</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.00</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.41</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>MDP4</td><td rowspan=1 colspan=1>107</td><td rowspan=1 colspan=1>0.99</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>0.57</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.60</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.96</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.41</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>QC 1</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>0.56</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.24</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.31</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.19</td><td rowspan=1 colspan=1>3.5</td><td rowspan=1 colspan=1>1.47</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>QC 2</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.68</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.36</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.26</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>1.73</td><td rowspan=1 colspan=1>2.2</td></tr></table>

Units: SD $=$ mmol/mol HbA1c, $C V = \%$

# (iii) Total Error at Decision Levels

The bias estimation values determined in the method comparison study and precision estimates determined in the precision study were used to determine the total error at each of the levels listed in Tables H and I. Total error was calculated as follows:

$$
\% T E = | \% B i a s | + 1 . 9 6 \times \% C V \times \left( 1 + \frac { \% B i a s } { 1 0 0 } \right)
$$

Table H. Total Error Summary, Passing-Bablok   

<table><tr><td rowspan=1 colspan=1>%HbA1cDecision Level</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-1.10</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-1.24</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.5</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-1.33</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>4.4</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-1.45</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>4.9</td></tr></table>

Table I. Total Error Summary, Deming   

<table><tr><td rowspan=1 colspan=1>%HbA1cDecision Level</td><td rowspan=1 colspan=1>% Bias</td><td rowspan=1 colspan=1>% CV</td><td rowspan=1 colspan=1>%TE</td></tr><tr><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>-1.16</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.8</td></tr><tr><td rowspan=1 colspan=1>6.5</td><td rowspan=1 colspan=1>-1.40</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>4.7</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>-1.55</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>-1.77</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>5.2</td></tr></table>

# (iv) Endogenous and Exogenous Interference

Testing to determine the interference bias of various endogenous interferents on the Dimension® Hemoglobin A1C Assay was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition. The effect of each interferent was evaluated using a paired difference analysis. Four replicates were tested at each of two HbA1c levels: $6 . 5 \% \pm 1 . 0 \%$ and $8 . 0 \% \pm 1 . 0 \%$ . No significant interference (i.e., greater than $\pm 5 . 0 \%$ ) was observed for the potential interferents at the concentrations listed in Table J.

# SIEMENS

Table J. Endogenous and Exogenous Interference   

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Concentration</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>100 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Ascorbic acid</td><td rowspan=1 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calcium dobesilate</td><td rowspan=1 colspan=1>20mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin(Conjugated)</td><td rowspan=1 colspan=1>66S mg/dL</td></tr><tr><td rowspan=1 colspan=1>Bilirubin (Unconjugated)</td><td rowspan=1 colspan=1>66smg/dL</td></tr><tr><td rowspan=1 colspan=1>Cefoxin sodium</td><td rowspan=1 colspan=1>250 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>503mg/dL</td></tr><tr><td rowspan=1 colspan=1>Cyclosporin</td><td rowspan=1 colspan=1>1.66s mg/dL</td></tr><tr><td rowspan=1 colspan=1>Doxycycline hyclate</td><td rowspan=1 colspan=1>5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>2000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>5 U/mL</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>50 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Insulin</td><td rowspan=1 colspan=1>593 μU/mL</td></tr><tr><td rowspan=1 colspan=1>Intralipid</td><td rowspan=1 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Levodopa</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metformin</td><td rowspan=1 colspan=1>4 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Methyldopa</td><td rowspan=1 colspan=1>2 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Metronidazole</td><td rowspan=1 colspan=1>20 mg/dL</td></tr><tr><td rowspan=1 colspan=1>N-acetylcysteine</td><td rowspan=1 colspan=1>166.3 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Phenylbutazone</td><td rowspan=1 colspan=1>40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Protein: Total</td><td rowspan=1 colspan=1>22 g/dL</td></tr><tr><td rowspan=1 colspan=1>Rheumatoid Factor</td><td rowspan=1 colspan=1>750 IU/mL</td></tr><tr><td rowspan=1 colspan=1>Rifampicin</td><td rowspan=1 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Rosiglitazone</td><td rowspan=1 colspan=1>0.8mg/dL</td></tr><tr><td rowspan=1 colspan=1>Salicylic acid</td><td rowspan=1 colspan=1>60 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>10 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>600 mg/dL</td></tr></table>

# (v) Hemoglobin Variant Interference

Interference testing to determine the effect of hemoglobin variants on the Dimension® Hemoglobin A1C Assay was performed according to CLSI EP07-A2, Interference Testing in Clinical Chemistry; Approved Guideline – Second Edition. Anticoagulated human blood samples with known concentrations of hemoglobin variant and HbA1c were analyzed. The effect of each hemoglobin variant on assay performance was evaluated comparing the mean observed %HbA1c values to the mean expected %HbA1c values. Four (4) replicates were tested for each sample. No significant interference bias (i.e., greater than $\pm 5 . 0 \%$ ) was observed for HbC, HbD, HbE, and HbA2. Significant interference bias was observed for HbF. Results are presented in Tables K and L.

Table K. Hemoglobin Variant Samples   

<table><tr><td rowspan=1 colspan=1>Hb Variant</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range (% Variant)</td><td rowspan=1 colspan=1>Range (%HbA1c)</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>26.1 to 40.0</td><td rowspan=1 colspan=1>4.4 to 15.7</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>24.8 to 38.4</td><td rowspan=1 colspan=1>5.0 to13.0</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>19.7 to 30.4</td><td rowspan=1 colspan=1>4.7 to 11.0</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>27.2 to 36.3</td><td rowspan=1 colspan=1>5.3 to 14.0</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>4.3 to 6.2</td><td rowspan=1 colspan=1>5.1 to 8.4</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4.3 to 29.3</td><td rowspan=1 colspan=1>4.3 to 10.1</td></tr></table>

Table L. Hemoglobin Variant Interference   

<table><tr><td rowspan=2 colspan=1>Hb Variant</td><td rowspan=1 colspan=2>Relative %Bias [Range of %Bias]Observed to Reference Method</td></tr><tr><td rowspan=1 colspan=1>HbA1c ~6%</td><td rowspan=1 colspan=1>HbA1c ~8%</td></tr><tr><td rowspan=1 colspan=1>HbC</td><td rowspan=1 colspan=1>-1.0%[-5.0% to 4.9%]</td><td rowspan=1 colspan=1>-0.9%[-4.6% to 4.4%]</td></tr><tr><td rowspan=1 colspan=1>HbD</td><td rowspan=1 colspan=1>-2.2%[-4.9% to 4.4%]</td><td rowspan=1 colspan=1>-2.5%[-4.4% to -1.3%]</td></tr><tr><td rowspan=1 colspan=1>HbE</td><td rowspan=1 colspan=1>-2.1%[-4.9% to 3.1%]</td><td rowspan=1 colspan=1>-2.5%[-4.3% to -1.0%]</td></tr><tr><td rowspan=1 colspan=1>HbS</td><td rowspan=1 colspan=1>-1.3%[-4.7% to 4.9%]</td><td rowspan=1 colspan=1>-2.0%[-4.9% to 3.5%]</td></tr><tr><td rowspan=1 colspan=1>HbA2</td><td rowspan=1 colspan=1>0.1%[-4.8% to 3.6%]</td><td rowspan=1 colspan=1>-2.0%[-3.0% to -1.1%]</td></tr><tr><td rowspan=1 colspan=1>HbF</td><td rowspan=1 colspan=1>-23.2%[-30.3% to 1.2%]</td><td rowspan=1 colspan=1>-24.7%[-25.8% to -23.3%]</td></tr></table>

# (vi) Hemoglobin Derivatives

Interference testing to determine the effect of hemoglobin derivatives, including acetylated hemoglobin, carbamylated hemoglobin, labile hemoglobin, and hemoglobin fractions on the Dimension $\textcircled{8}$ A1C assay was performed in accordance with CLSI document EP07-A2. Inaccuracies (biases) due to these substances are less than or equal to $5 \%$ at Hemoglobin A1c concentrations of $5 . 0 \% \pm 1 . 0 \%$ , $6 . 5 \% \pm 1 . 0 \%$ , and $8 . 0 \% \pm 1 . 0 \%$ .

Acetylated Hemoglobin with $\geq 5 0 { \mathrm { ~ m g / d L } }$ of acetylsalicylic acid Carbamylated Hemoglobin with $\geq 1 0 \ : \mathrm { m m o l / L }$ of Cyanate Labile Hemoglobin with $\geq 1 5 0 0 \mathrm { m g / d L }$ of Glucose

(vii) Linearity

Linearity testing was conducted CLSI EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline. Nine (9) samples with HbA1c levels across the assay range were prepared and tested. Four (4) replicates were tested at each level. No deviations from linearity were observed for results from 3.6 to $1 5 . 9 \%$ HbA1c.

(viii) Limit of Blank (LoB) and Limit of Detection (LoD)

Limit of Blank (LoB) and Limit of Detection (LoD) testing was conducted in accordance with CLSI EP17-A2, Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures. The LoB was determined using 60 determinations with 5 blank samples each for tHb and 75 determinations with 5 blank samples each for $\%$ HbA1c/HbA1c. The LoD was determined using 60 determinations, with 5 low level samples each for tHb and 75 determinations with 5 low samples each for $\%$ HbA1c/HbA1c. Results are presented in Table M.

Table M. Limit of Blank / Limit of Detection   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>HbA1c (%)</td><td rowspan=1 colspan=1>tHb (g/dL)</td><td rowspan=1 colspan=1>HbA1c (g/dL)</td></tr><tr><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.21</td></tr><tr><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.23</td></tr></table>

# SIEMENS

# (ix) Anticoagulant Comparison

Testing was performed to demonstrate equivalence between five different anticoagulants in accordance with CLSI EP09-A2, Method Comparison and Bias Estimation Using Patient Samples. Testing was performed to demonstrate equivalence between $\mathsf { K } _ { 2 }$ EDTA, ${ \sf K } _ { 3 }$ EDTA, Na Fluoride $N a _ { 2 }$ EDTA, Lithium Heparin and Na Fluoride/K-Oxalate collection tubes. HbA1c values were measured for each sample using the Dimension® Hemoglobin A1C Assay on the Dimension® RxL clinical chemistry system. Regression analysis was used to analyze the measured values using the $\mathsf { K } _ { 2 }$ EDTA samples as the comparator. The slope and y-intercept values were determined by Passing-Bablok and Deming regression. HbA1c values for the samples ranged from 4.7 to $12 . 8 \%$ . Results are presented in Tables N and O.

Table N. Anticoagulant Equivalence Summary, Passing-Bablok   

<table><tr><td rowspan=1 colspan=1>Anticoagulant(y axis)</td><td rowspan=1 colspan=1>Comparator(x axis)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-intercept[95% CI]</td></tr><tr><td rowspan=1 colspan=1>K3-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>0.994[0.982 to 1.007]</td><td rowspan=1 colspan=1>0.030[-0.055 to 0.102]</td></tr><tr><td rowspan=1 colspan=1>Na Fluoride/Na2-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>0.997[0.986 to 1.011]</td><td rowspan=1 colspan=1>0.006[-0.080 to 0.074]</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>1.006[0.995 to 1.019]</td><td rowspan=1 colspan=1>-0.038[-0.120 to 0.041]</td></tr><tr><td rowspan=1 colspan=1>Na Fluoride/K-Oxalate</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>1.010[0.994 to 1.023]</td><td rowspan=1 colspan=1>-0.037[-0.113 to 0.059]</td></tr></table>

Table O. Anticoagulant Equivalence Summary, Deming   

<table><tr><td rowspan=1 colspan=1>Anticoagulant(y axis)</td><td rowspan=1 colspan=1>Comparator(x axis)</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Slope[95% CI]</td><td rowspan=1 colspan=1>y-intercept[95% CI]</td></tr><tr><td rowspan=1 colspan=1>K3-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>0.997[0.978 to 1.015]</td><td rowspan=1 colspan=1>0.011[-0.102 to 0.124]</td></tr><tr><td rowspan=1 colspan=1>Na Fluoride/Na2-EDTA</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>1.003[0.985 to 1.020]</td><td rowspan=1 colspan=1>-0.033[-0.135 to 0.069]</td></tr><tr><td rowspan=1 colspan=1>Lithium Heparin</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>1.008[0.990 to 1.027]</td><td rowspan=1 colspan=1>-0.042[-0.152 to 0.068]</td></tr><tr><td rowspan=1 colspan=1>Na Fluoride/K-Oxalate</td><td rowspan=1 colspan=1>K2-EDTA</td><td rowspan=1 colspan=1>79</td><td rowspan=1 colspan=1>1.007[0.989 to 1.025]</td><td rowspan=1 colspan=1>-0.018[-0.127 to 0.091]</td></tr></table>

(x) Conclusion

The proposed Dimension® Hemoglobin A1C assay is substantially equivalent to the legally marketed predicate based on the similarities in intended use, technological characteristics, and performance testing presented above.